Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.

Cargill T. et al, (2023), JHEP reports : innovation in hepatology, 5

Re-valuation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): A feasibility study in women living with HIV in the UK.

Cicconi P. et al, (2022), HIV Med, 23, 390 - 396

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Flaxman A. et al, (2021), The Lancet, 398, 981 - 990

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478

MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.

Esposito I. et al, (2020), Science translational medicine, 12

First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.

Cicconi P. et al, (2020), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 70, 2073 - 2081

MHC-II invariant chain adjuvanted chimpanzee adenoviral and MVA hepatitis C vaccines elicit unprecedented levels of anti-viral T-cell immune responses in humans

Esposito I. et al, (2019), JOURNAL OF HEPATOLOGY, 70, E3 - E4

Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

Rossetti B. et al, (2018), HIV Medicine, 19, 619 - 628

Identification of novel resistance associated substitutions for sofosbuvir in HCV genotype 3a

Smith D. et al, (2018), JOURNAL OF HEPATOLOGY, 68, S269 - S269

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.

Hartnell F. et al, (2018), Frontiers in immunology, 9

Pathophysiology of ischaemic heart disease

Pocock MO. et al, (2017), Current Opinion in HIV and AIDS, 12, 548 - 553

Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort

Vita S. et al, (2017), JAIDS Journal of Acquired Immune Deficiency Syndromes, 74, 347 - 352

Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non–AIDS-Defining Events in a Large Cohort of HIV-Infected Patients

Lichtner M. et al, (2015), Journal of Infectious Diseases, 211, 178 - 186

Darunavir-based dual therapy in HIV experienced patients

Sterrantino G. et al, (2014), Journal of the International AIDS Society, 17, 19782 - 19782

The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy

Di Biagio A. et al, (2014), Journal of Medical Virology, 86, 1648 - 1655

Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy–Experienced Patients: A Multicenter Clinical Experience

Gazzola L. et al, (2014), HIV Clinical Trials, 15, 140 - 150

Darunavir-based dual therapy in HIV experienced patients.

Sterrantino G. et al, (2014), Journal of the International AIDS Society, 17

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort

Di Biagio A. et al, (2013), Journal of Antimicrobial Chemotherapy, 68, 200 - 205

Inconsistent condom use among HIV-positive women in the “Treatment as Prevention Era”: data from the Italian DIDI study

Cicconi P. et al, (2013), Journal of the International AIDS Society, 16, 18591 - 18591

Load More

Include forthcoming?